VRP Verona Pharma Plc

 
TIDMVRP 
 
 
   LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces today that it will report its 
financial results for the three months ended September 30, 2017 on 
Tuesday, November 7, 2017. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Standard Time (1:00 pm Greenwich Mean Time) on November 7, 
2017 to discuss the third quarter financial results and provide a 
clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 1550110 and dialing the following numbers: 
 
 
   -- (877)280-1254 or (646)254-3388 for callers in the United States 
 
   -- 0800 279 5736 or 44(0)20 3427 1901 for callers in the United Kingdom 
 
   -- 0800 589 2673 or 49(0)69 2222 10619 for calls in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at www.veronapharma.com and clicking on the webcast link. 
 
   A webcast replay of the conference call [audio] will be available on the 
"Investors" page of Verona Pharma's website at www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function as compared to 
placebo, and has shown clinically meaningful and statistically 
significant improvements in lung function when administered in addition 
to frequently used short- and long-acting bronchodilators as compared to 
such bronchodilators administered as a single agent. Verona Pharma is 
developing RPL554 for the treatment of chronic obstructive pulmonary 
disease (COPD) and cystic fibrosis (CF), and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison   SNELVeronaPharma@stifel.com 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins             veronapharma@fticonsulting.com 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                        Tel: +1 203-682-8251 
                                                    James.Heins@icrinc.com 
Stephanie Carrington                               Tel. +1 646-277-1282 
                                                    Stephanie.Carrington@icrinc.com 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

October 31, 2017 03:00 ET (07:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024